Zogenix, Inc. Announces Proposed Convertible Senior Notes Offering
September 22, 2020 16:14 ET
|
Zogenix, Inc
EMERYVILLE, Calif., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX) today announced its intention to offer, subject to market and other conditions, $200,000,000 aggregate principal...
CORRECTING and REPLACING - Zogenix Appoints Three Industry Leaders to Its Board of Directors
September 21, 2020 20:04 ET
|
Zogenix, Inc
Correction: In this updated news release issued September 21, 2020 by Zogenix, Inc, the name of the organization, WorldWideWomen, has been corrected. The full corrected press release follows. ...
Zogenix Appoints Three Industry Leaders to Its Board of Directors
September 21, 2020 08:00 ET
|
Zogenix, Inc
EMERYVILLE, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced the...
Zogenix Announces Positive Top-Line Results from its Third Pivotal Phase 3 Clinical Trial (Study 3) of FINTEPLA® in Dravet Syndrome
September 10, 2020 08:00 ET
|
Zogenix, Inc
Results corroborate highly statistically significant convulsive seizure reductions seen in earlier multinational Phase 3 studies of FINTEPLA in Dravet syndrome FINTEPLA at 0.7 mg/kg/day achieved a...
Zogenix Provides Corporate Update and Reports Second Quarter 2020 Financial Results
August 05, 2020 16:01 ET
|
Zogenix, Inc
FINTEPLA® (fenfluramine) in Dravet syndrome is now FDA approved and commercially launched in the U.S.More than 230 prescribers have already completed FINTEPLA REMS enrollment and certification FDA...
Zogenix to Release Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 5
July 29, 2020 08:00 ET
|
Zogenix, Inc
EMERYVILLE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its...
FDA Approves FINTEPLA® (fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome
June 25, 2020 20:49 ET
|
Zogenix, Inc
FINTEPLA® significantly and substantially reduced convulsive seizure frequency in patients whose seizures were not adequately controlled on other medications, as observed in two phase 3...
Zogenix Introduces New Resources for Dravet Syndrome Siblings
June 12, 2020 08:00 ET
|
Zogenix, Inc
EMERYVILLE, Calif., June 12, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced the introduction in the U.S. of...
Zogenix Launches Shine Forward with Dravet, a New Source of Inspiring Ideas for Parents of Children Living with Dravet Syndrome
May 15, 2020 08:00 ET
|
Zogenix, Inc
EMERYVILLE, Calif., May 15, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced the U.S. launch of Shine Forward...
Zogenix to Participate in the BofA Securities 2020 Virtual Healthcare Conference
May 06, 2020 08:00 ET
|
Zogenix, Inc
EMERYVILLE, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D.,...